AI assistant
Sending…
MADRIGAL PHARMACEUTICALS, INC. — Director's Dealing 2016
Nov 4, 2016
30608_dirs_2016-11-04_bb09278e-7838-4459-bfb8-9965d5ddf891.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK: 0001157601
Period of Report: 2016-07-22
Reporting Person: CRAVES FRED B (Director, 10% Owner)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-07-22 | Stock Option (Right to Buy) | $9.45 | A | 20000 | Acquired | 2026-07-22 | Common Stock (20000) | Direct |
Footnotes
F1: This report amends the original report to reflect the correct exercise price of $9.45 per share.
F2: Fifty percent (50%) of the option vests on July 22, 2017 and thereafter it vests at a rate of twelve and one-half percent (12.5%) per quarter for four (4) successive quarters.
More from MADRIGAL PHARMACEUTICALS, INC.
Interim / Quarterly Report
2026
May 6
Earnings Release
2026
May 6
Annual Report
2026
Apr 28
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Feb 24
Annual Report
2026
Feb 19
Earnings Release
2026
Feb 19
Regulatory Filings
2026
Jan 30
Director's Dealing
2026
Jan 26